NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
Updated: Sep 16, 2022
NCT03269136
MAGNETISMM-1
RRMM
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Sponsor
ClinicalTrials.gov Identifier: NCT04649359
Official Title: A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF-06863135, A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)
First Posted : August 31, 2017
Click here for details on ClinicalTrials.gov
Elranatamab (Code C146860)
Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135
B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135
BCMA x CD3 Bispecific Antibody PF-06863135
BCMA-CD3 Bispecific Ab PF-06863135
Elranatamab
ELRANATAMAB
PF 06863135
PF-06863135
PF06863135
RN 613
RN-613
RN613
Drug: PF-06863135 monotherapy IV or SC
Drug: PF-06863135 + dexamethasone (Decadron)
Drug: PF-06863135 + lenalidomide (Revlimid)
Drug: PF-06863135 + pomalidomide (Pomalyst)
MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)
Abstract: S192
Type: Oral Presentation
Session title: T cell re-directing therapies in relapsed/refractory multiple myeloma
EHA Library. 06/09/21
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Abstract 8006
2021 ASCO Annual Meeting
895 Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma
Hematology Disease Topics & Pathways:
Biological, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Myeloid Malignancies
Monday, December 13, 2021: 6:15 PM
- Multiple Locations
- International Study
- Illinois: University of Chicago
- Iowa: University of Iowa Iowa city
- Massachusetts: Massachusetts General Hospital Boston
- New York: Memorial Sloan-Kettering Cancer Center New York
- North Carolina: Duke University Hospital Durham
- Texas: Baylor University Medical Center Dallas
Locations
United States, California
United States, Georgia
United States, Illinois
United States, Iowa
United States, Louisiana
United States, Massachusetts
United States, New Jersey
United States, New York
United States, North Carolina
United States, Tennessee
United States, Texas
Canada, Alberta
Canada, Ontario
Canada, Quebec
RELATED POSTS
MAGNETISMM-2
NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2
MagnetisMM-3
NCT04649359: Phase 2: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma - MagnetisMM-3
MagnetisMM-4
NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4
MagnetisMM-5
NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5
MagnetisMM-7
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
MagnetisMM-8
NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8
MagnetisMM-9
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)